X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2231) 2231
humans (2186) 2186
bortezomib (1401) 1401
male (1314) 1314
female (1158) 1158
pyrazines - therapeutic use (1110) 1110
middle aged (1069) 1069
pyrazines - adverse effects (1061) 1061
pyrazines - administration & dosage (919) 919
aged (905) 905
multiple myeloma - drug therapy (769) 769
adult (737) 737
oncology (706) 706
boronic acids - adverse effects (674) 674
boronic acids - administration & dosage (663) 663
boronic acids - therapeutic use (618) 618
treatment outcome (594) 594
hematology (524) 524
multiple myeloma (511) 511
pyrazines - pharmacology (478) 478
antineoplastic combined chemotherapy protocols - therapeutic use (470) 470
animals (451) 451
antineoplastic agents - therapeutic use (432) 432
sitagliptin phosphate (402) 402
antineoplastic agents - adverse effects (399) 399
diabetes mellitus, type 2 - drug therapy (340) 340
antineoplastic combined chemotherapy protocols - adverse effects (293) 293
therapy (292) 292
aged, 80 and over (290) 290
pharmacology & pharmacy (288) 288
care and treatment (287) 287
triazoles - therapeutic use (266) 266
cancer (252) 252
dexamethasone - administration & dosage (238) 238
dexamethasone (230) 230
drug therapy, combination (229) 229
hypoglycemic agents - therapeutic use (229) 229
dose-response relationship, drug (226) 226
thalidomide (214) 214
research (211) 211
drug therapy (210) 210
chemotherapy (209) 209
thalidomide - analogs & derivatives (209) 209
abridged index medicus (201) 201
boronic acids - pharmacology (201) 201
antineoplastic agents - administration & dosage (199) 199
triazoles - adverse effects (198) 198
mice (197) 197
stem-cell transplantation (195) 195
thalidomide - administration & dosage (189) 189
medicine & public health (186) 186
multiple-myeloma (181) 181
drug administration schedule (179) 179
endocrinology & metabolism (179) 179
recurrence (176) 176
sitagliptin (176) 176
type 2 diabetes (175) 175
clinical trials as topic (173) 173
protease inhibitors - therapeutic use (170) 170
apoptosis (169) 169
trial (169) 169
proteasome inhibitors (165) 165
hypoglycemic agents - adverse effects (162) 162
analysis (154) 154
hematology, oncology and palliative medicine (154) 154
multiple myeloma - pathology (152) 152
thalidomide - therapeutic use (150) 150
dosage and administration (147) 147
diabetes (146) 146
transplantation (146) 146
rats (142) 142
retrospective studies (140) 140
proteasome inhibitor bortezomib (138) 138
disease-free survival (137) 137
pyrazines - pharmacokinetics (137) 137
clinical trials (136) 136
dipeptidyl-peptidase iv inhibitors - therapeutic use (135) 135
antineoplastic agents - pharmacology (132) 132
article (132) 132
multiple myeloma - mortality (129) 129
medicine, general & internal (127) 127
time factors (127) 127
multiple myeloma - therapy (126) 126
triazoles - administration & dosage (126) 126
double-blind method (125) 125
lenalidomide (125) 125
survival (125) 125
combination (123) 123
risk factors (123) 123
efficacy (122) 122
double-blind (120) 120
follow-up studies (120) 120
prognosis (119) 119
multiple myeloma - complications (117) 117
hypoglycemic agents - administration & dosage (116) 116
peripheral neuropathy (116) 116
protease inhibitors - adverse effects (116) 116
thalidomide - adverse effects (116) 116
peripheral nervous system diseases - chemically induced (115) 115
antineoplastic combined chemotherapy protocols - administration & dosage (114) 114
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2276) 2276
Japanese (41) 41
Chinese (32) 32
German (26) 26
French (20) 20
Italian (11) 11
Spanish (11) 11
Swedish (6) 6
Russian (5) 5
Polish (4) 4
Czech (3) 3
Danish (3) 3
Hebrew (2) 2
Norwegian (2) 2
Dutch (1) 1
Finnish (1) 1
Hungarian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Diabetologia, ISSN 0012-186X, 12/2013, Volume 56, Issue 12, pp. 2582 - 2592
The aim of this work was to evaluate the efficacy and safety of canagliflozin vs placebo and sitagliptin in patients with type 2 diabetes who were being... 
Sodium glucose co-transporter 2 (SGLT2) inhibitor | Medicine & Public Health | Human Physiology | Canagliflozin | Metabolic Diseases | Internal Medicine | Sitagliptin | Metformin | Type 2 diabetes mellitus | GLIPIZIDE | ADD-ON | SULFONYLUREA | DAPAGLIFLOZIN | MELLITUS | INADEQUATE GLYCEMIC CONTROL | DIET | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | 52-WEEK | INHIBITOR | Blood Pressure | Triazoles - administration & dosage | Triazoles - adverse effects | Thiophenes - adverse effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Pyrazines - administration & dosage | Glycated Hemoglobin A - drug effects | Body Weight - drug effects | Lipids | Male | Thiophenes - administration & dosage | Metformin - adverse effects | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Female | Metformin - administration & dosage | Sitagliptin Phosphate | Drug Therapy, Combination | Glucosides - adverse effects | Fasting | Treatment Outcome | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Glucosides - administration & dosage | Adolescent | Pyrazines - adverse effects | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Care and treatment | Body weight | Glucose | Comparative analysis | Dextrose | Index Medicus
Journal Article
Gastroenterology, ISSN 0016-5085, 2011, Volume 141, Issue 1, pp. 150 - 156
Journal Article
DIABETES CARE, ISSN 0149-5992, 03/2014, Volume 37, Issue 3, pp. 740 - 750
Journal Article
Blood, ISSN 0006-4971, 08/2012, Volume 120, Issue 8, pp. 1589 - 1596
The Spanish Myeloma Group conducted a trial to compare bortezomib/thalidomide/dexamethasone (VTD) versus thalidomide/dexamethasone (TD) versus vincristine,... 
TRIAL | SURVIVAL | PLUS DEXAMETHASONE | COMPLETE REMISSION | HIGH-DOSE THERAPY | COMPLETE RESPONSE | DOXORUBICIN | PERIPHERAL NEUROPATHY | CONTINUED STANDARD CHEMOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Boronic Acids - toxicity | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Dexamethasone - toxicity | Induction Chemotherapy | Male | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Antineoplastic Agents - administration & dosage | Boronic Acids - therapeutic use | Antineoplastic Agents - toxicity | Multiple Myeloma - therapy | Pyrazines - toxicity | Antineoplastic Agents - adverse effects | Female | Boronic Acids - administration & dosage | Thalidomide - adverse effects | Bortezomib | Dexamethasone - administration & dosage | Multiple Myeloma - diagnosis | Thalidomide - administration & dosage | Thalidomide - toxicity | Antineoplastic Combined Chemotherapy Protocols - toxicity | Disease-Free Survival | Dexamethasone - therapeutic use | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrazines - adverse effects | Stem Cells - drug effects | Stem Cells - pathology | Aged | Hematopoietic Stem Cell Transplantation - methods | Thalidomide - therapeutic use | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2014, Volume 32, Issue 7, pp. 634 - 640
Journal Article
Blood, ISSN 0006-4971, 08/2010, Volume 116, Issue 5, pp. 679 - 686
Journal Article
Diabetes Care, ISSN 0149-5992, 2014, Volume 37, Issue 8, pp. 2149 - 2158
OBJECTIVE To compare the efficacy and safety of two doses of once-weekly dulaglutide, a glucagon-like peptide 1 receptor agonist, to sitagliptin in... 
METFORMIN | GLYCEMIC CONTROL | PLACEBO | GLP-1 | GLUCAGON-LIKE PEPTIDE-1 | RECEPTOR AGONISTS | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | ANALOG LIRAGLUTIDE | OPEN-LABEL | INHIBITOR SITAGLIPTIN | Glycated Hemoglobin A - analysis | Triazoles - administration & dosage | Triazoles - adverse effects | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Immunoglobulin Fc Fragments - administration & dosage | Dose-Response Relationship, Drug | Hypoglycemic Agents - administration & dosage | Female | Metformin - administration & dosage | Sitagliptin Phosphate | Drug Therapy, Combination | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Double-Blind Method | Treatment Outcome | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Pyrazines - adverse effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Sitagliptin | Care and treatment | Dosage and administration | Safety and security measures | Comparative analysis | Clinical trials | Hemoglobin | Glycosylation | Diabetes | Product safety | Placebo effect | Index Medicus | Psychosocial Research | Nutrition | Education | Clinical Care
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9758, pp. 2075 - 2085
Journal Article